Highly selective allosteric modulator of the phosphoinositide 3-kinase data (PI3Kδ) roginolisib (IOA-244) in a dose escalation study of patients with refractory/relapsed follicular lymphoma (FL)

Industry Insight

Scientific innovation in uveal melanoma

6 March 2025

Industry Insight

Opportunities and challenges in oncology immunotherapy

4 February 2025

Industry Insight

Reflections from our CEO

16 December 2024

Industry Insight

Pancreatic cancer – our commitment to scientific advances

21 November 2024

Industry Insight

A bold new era in global cancer drug discovery

5 July 2024

Industry Insight

A note from our CEO

20 June 2024

Industry Insight

Realising the potential of autotaxin therapy in cancer

14 June 2024

Industry Insight

PI3Kδ inhibitors offer serious promise in solid tumors

11 May 2024

Industry Insight

Emerging therapies offer hope for uveal melanoma patients

2 April 2024